SCHEMBL2195778

SCHEMBL2195778

IN(I)C1CCCCCC1.[Pt]=c1n(Cc2ccccc2)ccn1Cc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.41
CNR1 P21554 2/20 0.41
ALDH1A1 P00352 3/20 0.39
HPGD P15428 2/20 0.39
KDM4E B2RXH2 2/20 0.39
USP2 O75604 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CYP19A1 P11511 1/20 0.36
AGER Q15109 1/20 0.36
VEGFA P15692 2/20 0.35
EGLN1 Q9GZT9 2/20 0.35
G6PC1 P35575 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
MITF O75030 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35
PAX8 Q06710 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2195352 1.00 CNR2 (0.41) CNR2CNR1ALDH1A1HPGDKDM4E
SCHEMBL2195510 0.99 CNR1 (0.39) CNR2CNR1ALDH1A1HPGDKDM4E
SCHEMBL2195569 0.97 CNR1 (0.37) CNR2CNR1ALDH1A1HPGDKDM4E
SCHEMBL2192049 0.93 KDM4E (0.37) CNR2CNR1ALDH1A1KDM4EVEGFA
SCHEMBL2196206 0.91 CNR1 (0.37) CNR2CNR1ALDH1A1HPGDKDM4E
SCHEMBL2196582 0.89 CNR1 (0.36) CNR2CNR1ALDH1A1HPGDKDM4E
SCHEMBL2192733 0.87 CNR1 (0.39) CNR2CNR1ALDH1A1HPGDKDM4E
SCHEMBL2196906 0.86 AGER (0.39) CNR2CNR1ALDH1A1HPGDKDM4E
SCHEMBL2192592 0.76 MAPT (0.39) CNR2CNR1ALDH1A1
SCHEMBL2194293 0.76 MAPT (0.39) CNR2CNR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980875-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-17 US claimed
US-8481522-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-07-09 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 CNR2 203/4885CNR1 278/4885ALDH1A1 1989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.